![](assets_2023/img/relations_bg_top.png)
Captor Therapeutics ®
News
![miniatura](https://captortherapeutics.com/userfiles/news/65-1684392477_thumb.jpg)
September 20, 2022
Captor Therapeutics announces participation in upcoming scientific, investor, and partnering conferences in October 2022
![miniatura](https://captortherapeutics.com/userfiles/news/64-1684392483_thumb.jpg)
September 05, 2022
Captor Therapeutics' first half of 2022 marked by significant progress in R&D and preparations for the commencement of clinical trials
![miniatura](https://captortherapeutics.com/userfiles/news/63-1684392488_thumb.jpg)
August 10, 2022
Captor Therapeutics nominates the molecular glue CPT-6281 as drug candidate to enter CTA/IND-enabling studies for the treatment of hepatocellular carcinoma
![miniatura](https://captortherapeutics.com/userfiles/news/60-1684392493_thumb.jpg)
July 21, 2022
Captor Therapeutics to attend Wedbush PacGrow Healthcare Conference 2022
![miniatura](https://captortherapeutics.com/userfiles/news/59-1684392498_thumb.jpg)
June 30, 2022
Zaproszenie na Walne Zgromadzenie
![miniatura](https://captortherapeutics.com/userfiles/news/58-1684392503_thumb.jpg)
May 31, 2022
Captor Therapeutics Q1 2022 report: company continues to generate exciting data on lead projects (CT-01, CT-02, CT-03), maintains strong financial position
![miniatura](https://captortherapeutics.com/userfiles/news/57-1684392552_thumb.jpg)
May 05, 2022
Captor Therapeutics to host R&D Day on May 18, 2022
![miniatura](https://captortherapeutics.com/userfiles/news/56-1684392558_thumb.jpg)
May 02, 2022
Captor Therapeutics has released its 2021 report. Recent quarterly results have seen significant R&D progress; The Company has sufficient funds for further research and is meeting expenditures on schedule